Detection of Three Novel Mutations in Exon 7 of FGFR3 Gene in Iraqi Patients with Bladder Cancer

The present study was carried out in Genetic Engineering and biotechnology Institute –Baghdad University during a period from October 2013 to October 2014, for detecting the role of genetic alterations of FGFR3 gene in Iraqi patients with bladder cancer. 50 patients with bladder cancer who admitted to Ghazi AlHariri Hospital in Baghdad and 25 healthy persons (age between 30 to 86 years) were included in this study. Total genomic DNA was isolated from blood samples for molecular analysis using specific primers for exon 7 of the gene FGFR3. The PCR amplified regions of the FGFR3 exon 7 of healthy and patients showed a molecular weight of about 120 bp. The analysis of mutation using restriction fragment length polymorphism (RFLP) was performed on PCR products of FGFR3 exon 7 using Hae II and TseI enzymes. These results showed that the PCR amplified regions of the FGFR3 exon 7 has only one restriction site for each enzymes. The REFLP molecular analysis of FGFR3 exon 7 of patient samples for both enzymes revealed one mutation in one patient include FGFR3 Arginine 248 Cysteine mutation. The DNA sequencing analysis of the exon 7 PCR products revealed that among 50 patients included in this study, 51 mutations were detected in exon 7. The mutations detected in exon 7 include three types, g.13515 del C, g.13510 del A and g.13529 ins A. The more frequent mutation was g.13515 del C which detected in 34 patients followed by g.13510 del A and g.13529 ins A mutations whic